Our data revealed that the addition of TIGIT blockade to MWA upregulated the expressions of CXCL9 and CXCL10 in TAMs and the expression of their receptor CXCR3 in T cells, which might restrain tumor growth and enhance antitumor immunity. Here, CXCR3 is linked to neoplasm.